Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Comparison of Two Jaktinib Formulations in Healthy Volunteers
NCT06132243Phase 1Completed
- Sponsor
- Zelgen
- Start
- Nov 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of jaktinib in myelofibrosis (MF) (2 arms), sponsored by Zelgen. Primary endpoints: Maximum Plasma Concentration up to 48 hours, Area Under the Curve (0-t) up to 48 hours and 1 more. Started Nov 2023; status: completed.
02
Drugs
jaktinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT06132243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06132243.